Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients (Q44131522)

30 November 2017

Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients (English)

1 reference

chronic renal insufficiency

30 November 2017

1 reference

3

1 reference

30 November 2017

8

1 reference

30 November 2017

9

Bengt Lindholm

1 reference

30 November 2017

6

Olof Heimburger

1 reference

30 November 2017

7

Peter Bárány

1 reference

30 November 2017

5

Björn Anderstam

1 reference

30 November 2017

1

Naohito Isoyama

1 reference

30 November 2017

2

Paul Leurs

1 reference

30 November 2017

4

Annette Bruchfeld

1 reference

PubMed ID

25074436

30 November 2017

language of work or name

English

0 references

publication date

28 July 2014

1 reference

Nephrology Dialysis Transplantation

30 November 2017

1 reference

30 November 2017

30

1 reference

30 November 2017

1

1 reference

30 November 2017

84-91

1 reference

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

30 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Cardiovascular biomarkers in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

RAGE and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

RAGE regulation and signaling in inflammation and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

The AGE-receptor in the pathogenesis of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

sRAGE and risk of diabetes, cardiovascular disease, and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Soluble receptor for advanced glycation end products in patients with decreased renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Factors predicting malnutrition in hemodialysis patients: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Topological research on diamagnetic susceptibilities of organic compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

S100A12 (EN-RAGE) in monitoring Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

S100A12 gene expression is increased in peripheral leukocytes in chronic kidney disease stage 4-5 patients with cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

Serum S100A12 (EN-RAGE) Levels in Patients with Decreased Renal Function and Subclinical Chronic Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: Aprospective observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU259

21 January 2018

Identifiers

DOI

10.1093/NDT/GFU259

1 reference

30 November 2017

1 reference

PubMed ID

25074436